Marinus Pharmaceuticals (NASDAQ:MRNS) Releases Earnings Results

Marinus Pharmaceuticals (NASDAQ:MRNS) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02, reports. The business had revenue of $8.54 million during the quarter, compared to analysts’ expectations of $8.95 million. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative return on equity of 7,831.35%.

Marinus Pharmaceuticals Trading Up 0.5 %

Shares of MRNS opened at $0.31 on Friday. The company’s 50 day simple moving average is $1.26 and its 200-day simple moving average is $1.33. The firm has a market cap of $17.11 million, a PE ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently bought and sold shares of MRNS. Suvretta Capital Management LLC raised its holdings in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Marinus Pharmaceuticals by 31.4% in the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares during the period. Vanguard Group Inc. raised its stake in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the last quarter. abrdn plc lifted its position in Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares during the period. Finally, GSA Capital Partners LLP grew its stake in shares of Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Analysts Set New Price Targets

MRNS has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday. Royal Bank of Canada cut their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Nine analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.